1. Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors

   • Zhumei Zhan
   • Wei Guo
   • Ou Bai

   Review Article 09 January 2023 Pages: 249 - 259

   

2. Prognostic value of multiparametric cardiac magnetic resonance in sickle cell patients

   • Antonella Meloni
   • Laura Pistoia
   • Filippo Cademartiri

   Original Article 02 December 2022 Pages: 261 - 270

   

3. Sleep disordered breathing and its relation to stroke and pulmonary hypertension in children with sickle cell disease: a single-center cross-sectional study

   • Azza Tantawy
   • Nayera El-Sherif
   • Fatma S. E. Ebeid

   Original Article Open access 16 January 2023 Pages: 271 - 281

   

4. Comparative efficacy and safety of restrictive versus liberal transfusion thresholds in anemic preterm infants: a meta-analysis of 12 randomized controlled trials

   • Xiaoling Fu
   • Xingdan Zhao
   • Qian Zhang

   Original Article Open access 21 December 2022 Pages: 283 - 297

   

5. Long noncoding RNA FAM157C contributes to clonal proliferation in paroxysmal nocturnal hemoglobinuria

   • Honglei Wang
   • Hui Liu
   • Rong Fu

   Original Article Open access 06 January 2023 Pages: 299 - 309

   

6. Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study

   • Ulrich Germing
   • Pierre Fenaux
   • Guillermo Garcia-Manero

   Original Article Open access 13 January 2023 Pages: 311 - 321

   

7. Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy

   • Piroska Klement
   • Walter Fiedler
   • Michael Heuser

   Original Article Open access 28 December 2022 Pages: 323 - 328

   

8. Re-induction therapy in patients with acute myeloid leukemia not in complete remission after the first course of treatment

   • Weijia Fu
   • Yue Hu
   • Jianmin Yang

   Original Article 12 January 2023 Pages: 329 - 335

   

9. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia

   • Yun-wei Zhang
   • Long Su
   • Su-jun Gao

   Original Article 15 November 2022 Pages: 337 - 347

   

10. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group

    • Steffen Koschmieder
    • Susanne Isfort
    • for the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

    Original Article Open access 23 December 2022 Pages: 349 - 358

    

11. Prognostic significance of absolute monocyte count and lymphocyte to monocyte ratio in mucosa-associated lymphoid tissue (MALT) lymphoma

    • Chun-Yu Shang
    • Jia-Zhu Wu
    • Wei Xu

    Original Article 10 January 2023 Pages: 359 - 367

    

12. Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma

    • Yubin Kang
    • Pasupathi Sundaramoorthy
    • Terry Plasse

    Original Article 03 December 2022 Pages: 369 - 383

    

13. A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphoma

    • Francesco Gaudio
    • Giacomo Loseto
    • Pellegrino Musto

    Original Article 16 January 2023 Pages: 385 - 392

    

14. Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab

    • Fei Wang
    • Luo Lu
    • Weiying Gu

    Original Article 21 January 2023 Pages: 393 - 402

    

15. BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2

    • Judith Konrat
    • Wiebke Rösler
    • Thorsten Zenz

    Original Article Open access 10 December 2022 Pages: 403 - 406

    

16. Allogeneic stem cell transplantation in patients with a prior history of prostate cancer

    • Raffaele Palmieri
    • Robert B. Montgomery
    • Kristine Doney

    Original Article 17 November 2022 Pages: 407 - 412

17. Sequential low-dose CT thorax scans to determine invasive pulmonary fungal infection incidence after allogeneic hematopoietic cell transplantation

    • K. Enger
    • X. Tonnar
    • H. Bertz

    Original Article Open access 03 December 2022 Pages: 413 - 420

18. Exposure of anti-infective drugs and the dynamic changes of the gut microbiota during gastrointestinal mucositis in autologous stem cell transplant patients: a pilot study

    • Anne-Grete Märtson
    • Ana Rita da Silva Ferreira
    • Jan-Willem C. Alffenaar

    Original Article Open access 17 January 2023 Pages: 421 - 427

    

19. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma

    • Carmen Martínez
    • Manuel Espeso de Haro
    • on behalf of Grupo Español de Linfoma y Trasplante de Médula Ósea (GELTAMO) y Grupo Español de Trasplante (GETH)

    Original Article 12 November 2022 Pages: 429 - 437

    

20. The association between nutritional risk index and ICU outcomes across hematologic malignancy patients with acute respiratory failure

    • Riddhi Kundu
    • Rena Seeger
    • Laveena Munshi

    Original Article 21 December 2022 Pages: 439 - 445

    

21. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain

    • Ariana Ortuzar
    • María Laura Fox
    • Santiago Osorio

    Original Article 23 November 2022 Pages: 447 - 456

    

22. Real-world experience and considerations on concomitant caplacizumab and anticoagulation in thrombotic thrombocytopenic purpura

    • Benson Meek
    • Nuti Desai
    • Justin Arnall

    Letter to the Editor 28 November 2022 Pages: 457 - 459

23. Gastric adenocarcinoma following CD19-directed chimeric antigen receptor T cell therapy

    • James A. Davis
    • Jagoda Misniakiewicz
    • Brian T. Hess

    Letter to the Editor 16 November 2022 Pages: 461 - 462

    

24. Impact of antithymocyte globulin on blood cyclosporin A levels in aplastic anemia patients

    • Yuya Futagi
    • Yukio Suga
    • Yoshimichi Sai

    Letter to the Editor 26 November 2022 Pages: 463 - 465

25. Magnitude of cumulative iron overload correlates with the severity of anemia in untreated non-transfusion-dependent β-thalassemia

    • Khaled M. Musallam
    • Maria Domenica Cappellini
    • Ali T. Taher

    Letter to the Editor 14 November 2022 Pages: 467 - 469

    

26. EBV-positive diffuse large B-cell lymphoma following alemtuzumab therapy for T-cell prolymphocytic leukemia

    • Adam Suleman
    • Hubert Tsui
    • Lee Mozessohn

    Letter to the Editor 28 November 2022 Pages: 471 - 472

    

27. Acute myeloid leukemia patients with NUP98::NSD1 showing initially poor treatment response can benefit from FLT3 inhibitors and venetoclax as well as HSCT

    • Haimin Sun
    • Han Yan
    • Sujiang Zhang

    Letter to the Editor 24 November 2022 Pages: 473 - 475

28. Inherited transmission of the CSF3R T618I mutation: a familial report

    • Istemi Serin
    • Tahir Alper Cinli
    • Osman Yokus

    Letter to the Editor 15 November 2022 Pages: 477 - 479

    

29. Neurolymphomatosis of cranial nerves as the responsible lesions for the vocal cord paralysis and facial nerve palsy in a patient with diffuse large B-cell lymphoma

    • Yu Inoue
    • Koichi Hirakawa
    • Junya Kuroda

    Letter to the Editor 14 November 2022 Pages: 481 - 482

    

30. Disseminated Mycobacterium haemophilum infection during alemtuzumab treatment of T-cell prolymphocytic leukemia

    • Carol Y. M. Cheung
    • Rock Y. Y. Leung
    • Yok-lam Kwong

    Letter to the Editor 13 January 2023 Pages: 483 - 485

    

31. Vinblastine as a bridge to 7 + 3 in acute myeloid leukaemia

    • Fernando De la Garza-Salazar
    • Andrés Gómez-De León
    • Perla R. Colunga-Pedraza

    Letter to the Editor 18 January 2023 Pages: 487 - 489

    

32. Early cerebrospinal fluid infiltration in TP53-mutated blastic plasmacytoid dendritic cell neoplasm

    • Simon Michaelis
    • Angelika Pichler
    • Dietmar Enko

    Letter to the Editor 16 December 2022 Pages: 491 - 493

    

33. The KMT2A rearrangement is an early event prior to KMT2A-PTD in AML patients with both molecular aberrations

    • Jiayu Huang
    • Yongmei Zhu
    • Sujiang Zhang

    Letter to the Editor 16 December 2022 Pages: 495 - 497

34. Therapy-related myelodysplastic syndrome with monosomy 7 and metastatic renal cell carcinoma successfully treated with nivolumab: two birds with one stone

    • Lana Jajac Bručić
    • Ivan Krečak

    Letter to the Editor 20 December 2022 Pages: 499 - 500

    

35. Correction to: A real‑world experience of eltrombopag plus rabbit antithymocyte immunoglobulin–based IST in Chinese patients with severe aplastic anemia

    • Yuanyuan Jin
    • Ruixin Li
    • Jiangyong Li

    Correction 26 January 2023 Pages: 501 - 501